![Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia | Nature Communications Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-27945-7/MediaObjects/41467_2021_27945_Fig1_HTML.png)
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia | Nature Communications
![Frontiers | The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies Frontiers | The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies](https://www.frontiersin.org/files/Articles/540270/fimmu-11-01951-HTML/image_m/fimmu-11-01951-g001.jpg)
Frontiers | The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
![Frontiers | Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies Frontiers | Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies](https://www.frontiersin.org/files/Articles/531056/fimmu-11-00969-HTML/image_m/fimmu-11-00969-g001.jpg)
Frontiers | Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
![Antibodies | Free Full-Text | Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity Antibodies | Free Full-Text | Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity](https://www.mdpi.com/antibodies/antibodies-07-00019/article_deploy/html/images/antibodies-07-00019-g002.png)
Antibodies | Free Full-Text | Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
![Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle - ScienceDirect Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589909019300048-gr1.jpg)
Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle - ScienceDirect
![Effects of blood processing and sample storage on the stability of biotherapeutics and anti-drug antibodies | Bioanalysis Effects of blood processing and sample storage on the stability of biotherapeutics and anti-drug antibodies | Bioanalysis](https://www.future-science.com/cms/10.4155/bio.15.66/asset/images/medium/figure1.gif)
Effects of blood processing and sample storage on the stability of biotherapeutics and anti-drug antibodies | Bioanalysis
![Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-08682-3/MediaObjects/41598_2022_8682_Fig1_HTML.png)
Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports
![Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial - Brun - 2022 - Journal of Internal Medicine - Wiley Online Library Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial - Brun - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/e0cad91a-767c-441b-8823-c141cf1a3e81/joim13495-gra-0001-m.jpg)
Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial - Brun - 2022 - Journal of Internal Medicine - Wiley Online Library
![Antibodies | Free Full-Text | Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity Antibodies | Free Full-Text | Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity](https://www.mdpi.com/antibodies/antibodies-07-00019/article_deploy/html/images/antibodies-07-00019-g001.png)
Antibodies | Free Full-Text | Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
![Frontiers | Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists Frontiers | Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists](https://www.frontiersin.org/files/Articles/498409/fimmu-10-02921-HTML/image_m/fimmu-10-02921-g001.jpg)
Frontiers | Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists
![Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis - ScienceDirect Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0003269717304311-gr7.jpg)